现代肿瘤医学
現代腫瘤醫學
현대종류의학
Journal of Modern Oncology
2015年
19期
2871-2874
,共4页
T790M%非小细胞肺癌%EGFR - TKI%耐药
T790M%非小細胞肺癌%EGFR - TKI%耐藥
T790M%비소세포폐암%EGFR - TKI%내약
T790M%non - small - cell lung cancer%epidermal growth factor receptor - tyrosine kinase inhibitors%drug resistance
表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor - tyrosine kinase inhibitor， EGFR - TKI）治疗非小细胞肺癌已获得较好的疗效，患者生活质量明显改善。但 EGFR - TKI 耐药似乎成为了靶向治疗的瓶颈，耐药的产生可能存在多种机制，包括 T790M 突变、K - ras 基因突变、C - Met 基因扩增、BRAF 基因突变、BIM 多态性缺失、EML4- ALK 融合基因突变及上皮间充质转化等，其中最常见的是 T790M基因突变。目前研究表明，T790M 基因还可能具有一定预测疗效和预后的作用。本文将简要介绍 T790M 基因的发现、起源、作用机制及预后，并主要针对 EGFR - TKIs 耐药后的治疗策略进行综述。
錶皮生長因子受體酪氨痠激酶抑製劑（epidermal growth factor receptor - tyrosine kinase inhibitor， EGFR - TKI）治療非小細胞肺癌已穫得較好的療效，患者生活質量明顯改善。但 EGFR - TKI 耐藥似乎成為瞭靶嚮治療的瓶頸，耐藥的產生可能存在多種機製，包括 T790M 突變、K - ras 基因突變、C - Met 基因擴增、BRAF 基因突變、BIM 多態性缺失、EML4- ALK 融閤基因突變及上皮間充質轉化等，其中最常見的是 T790M基因突變。目前研究錶明，T790M 基因還可能具有一定預測療效和預後的作用。本文將簡要介紹 T790M 基因的髮現、起源、作用機製及預後，併主要針對 EGFR - TKIs 耐藥後的治療策略進行綜述。
표피생장인자수체락안산격매억제제（epidermal growth factor receptor - tyrosine kinase inhibitor， EGFR - TKI）치료비소세포폐암이획득교호적료효，환자생활질량명현개선。단 EGFR - TKI 내약사호성위료파향치료적병경，내약적산생가능존재다충궤제，포괄 T790M 돌변、K - ras 기인돌변、C - Met 기인확증、BRAF 기인돌변、BIM 다태성결실、EML4- ALK 융합기인돌변급상피간충질전화등，기중최상견적시 T790M기인돌변。목전연구표명，T790M 기인환가능구유일정예측료효화예후적작용。본문장간요개소 T790M 기인적발현、기원、작용궤제급예후，병주요침대 EGFR - TKIs 내약후적치료책략진행종술。
Tyrosine kinase inhibitors(EGFR - TKI)have shown favorable efficacy in non - small cell lung cancer, the patientˊs quality of life improved significantly. However,resistance to EGFR - TKI has become a problem of the targeted therapy. The resistance to EGFR - TKI have identified several mechanisms,which including T790M muta-tion,K - ras gene mutation,C - Met gene amplification,BRAF mutations,BIM deletion polymorphism,EML4 - ALK fusion gene mutation and epithelial - mesenchy - mal transition of small - cell lung cancer etc,of which the most com-mon is the T790M mutation . The present study indicates that,T790M mutation may play a important role in predicting the efficacy and prognosis. This review will introduce the discovery,origin,mechanism and prognosis of T790M,and mainly discusses the therapeutic strategy after EGFR - TKI resistance.
